ATE280157T1 - 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii - Google Patents

4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii

Info

Publication number
ATE280157T1
ATE280157T1 AT99953974T AT99953974T ATE280157T1 AT E280157 T1 ATE280157 T1 AT E280157T1 AT 99953974 T AT99953974 T AT 99953974T AT 99953974 T AT99953974 T AT 99953974T AT E280157 T1 ATE280157 T1 AT E280157T1
Authority
AT
Austria
Prior art keywords
ccr
aroyl
piperidine
receptor antagonists
iii
Prior art date
Application number
AT99953974T
Other languages
English (en)
Inventor
Leyi Gong
Denis John Kertesz
David Bernard Smith
Robert Stephen Wilhelm
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE280157T1 publication Critical patent/ATE280157T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99953974T 1998-11-17 1999-11-08 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii ATE280157T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10879698P 1998-11-17 1998-11-17
PCT/EP1999/008548 WO2000029377A1 (en) 1998-11-17 1999-11-08 4-aroyl-piperidin-ccr-3 receptor antagonists iii

Publications (1)

Publication Number Publication Date
ATE280157T1 true ATE280157T1 (de) 2004-11-15

Family

ID=22324087

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99953974T ATE280157T1 (de) 1998-11-17 1999-11-08 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii

Country Status (22)

Country Link
US (1) US6140344A (de)
EP (1) EP1131291B1 (de)
JP (1) JP3475177B2 (de)
KR (1) KR20010087395A (de)
CN (1) CN1163484C (de)
AR (1) AR029150A1 (de)
AT (1) ATE280157T1 (de)
AU (1) AU757747B2 (de)
BR (1) BR9915403A (de)
CA (1) CA2350722A1 (de)
CO (1) CO5150176A1 (de)
DE (2) DE69921351T2 (de)
ES (2) ES2230899T3 (de)
FR (1) FR2785902B1 (de)
GB (1) GB2343891B (de)
IT (1) IT1307062B1 (de)
PE (1) PE20001303A1 (de)
PT (1) PT1131291E (de)
TR (1) TR200101155T2 (de)
UY (1) UY25804A1 (de)
WO (1) WO2000029377A1 (de)
ZA (1) ZA200103249B (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2347909A1 (en) 1998-12-18 2000-06-22 Joseph B. Santella, Iii N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6605623B1 (en) 1998-12-18 2003-08-12 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2482100A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU2057200A (en) * 1998-12-18 2000-07-03 Du Pont Pharmaceuticals Company N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU4157500A (en) 1999-03-26 2000-10-16 Astrazeneca Ab Novel compounds
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
GB0017174D0 (en) * 2000-07-12 2000-08-30 Novartis Ag Organic compounds
TWI227231B (en) * 2000-07-12 2005-02-01 Novartis Ag 4-benzoyl-piperidine derivatives for treating conditions mediated by CCR-3
GB0021670D0 (en) 2000-09-04 2000-10-18 Astrazeneca Ab Chemical compounds
AR035205A1 (es) 2000-09-29 2004-05-05 Glaxo Group Ltd Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas
FR2821356A1 (fr) 2001-02-23 2002-08-30 Cerep Nouveaux derives d'arylcarbamates et d'arylurees, preparations et utilisations
GB0114699D0 (en) 2001-06-15 2001-08-08 Novartis Ag Organic compounds
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
SE0102809D0 (sv) * 2001-08-22 2001-08-22 Astrazeneca Ab Novel compounds
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
PL378753A1 (pl) 2003-02-27 2006-05-15 F.Hoffmann-La Roche Ag Antagoniści receptora CCR-3
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
EP1619193A4 (de) 2003-04-18 2010-08-11 Ono Pharmaceutical Co Spiropiperidinverbindung und deren medizinische verwendung
EP1680408A2 (de) * 2003-10-24 2006-07-19 F. Hoffmann-La Roche Ag Ccr3-rezeptorantagonisten
SE0400208D0 (sv) 2004-02-02 2004-02-02 Astrazeneca Ab Chemical compounds
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
EP1889622A4 (de) 2005-05-31 2009-12-23 Ono Pharmaceutical Co Spiropiperidinverbindung und deren medizinische verwendung
WO2007049771A1 (ja) 2005-10-28 2007-05-03 Ono Pharmaceutical Co., Ltd. 塩基性基を含有する化合物およびその用途
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
RU2008140144A (ru) 2006-03-10 2010-04-20 Оно Фармасьютикал Ко., Лтд. (Jp) Азотосодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента
US8618122B2 (en) 2006-05-16 2013-12-31 Ono Pharmaceutical Co., Ltd. Compound having acidic group which may be protected, and use thereof
WO2008016006A1 (fr) 2006-07-31 2008-02-07 Ono Pharmaceutical Co., Ltd. Composé auquel un groupe cyclique est lié par une liaison spiro et son utilisation
WO2010129351A1 (en) 2009-04-28 2010-11-11 Schepens Eye Research Institute Method to identify and treat age-related macular degeneration
WO2013080811A1 (ja) 2011-11-28 2013-06-06 国立大学法人名古屋大学 リンパ球性漏斗下垂体後葉炎のバイオマーカー及びその用途
US11584740B2 (en) 2017-09-13 2023-02-21 Syngenta Participations Ag Microbiocidal quinoline (thio)carboxamide derivatives
ES2904910T3 (es) * 2017-09-13 2022-04-06 Syngenta Participations Ag Derivados de quinolina (tio)carboxamida microbiocidas
CN111164076A (zh) 2017-09-13 2020-05-15 先正达参股股份有限公司 杀微生物的喹啉(硫代)甲酰胺衍生物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK159420C (da) * 1983-03-09 1991-03-11 Ciba Geigy Ag N-(piperidinyl-alkyl)-carboxamider og salte deraf, farmaceutiske praeparater indeholdende disse forbindelser samt anvendelsen af forbindelserne til fremstilling af antipsykotiske farmaceutiske praeparater
FI97540C (fi) * 1989-11-06 1997-01-10 Sanofi Sa Menetelmä terapeuttisesti käyttökelpoisten, aromaattisesti substituoitujen piperidiini- ja piperatsiinijohdannaisten valmistamiseksi
JPH041128A (ja) * 1990-03-07 1992-01-06 Ajinomoto Co Inc 抗不整脈薬
US5143923B1 (en) * 1991-04-29 1993-11-02 Hoechst-Roussel Pharmaceuticals Incorporated Benzoisothiazole-and benzisoxazole-3-carboxamides
DK60893D0 (da) * 1993-05-26 1993-05-26 Novo Nordisk As Piperidinderivater, deres fremstilling og anvendelse
WO1995000481A1 (en) * 1993-06-23 1995-01-05 Merrell Dow Pharmaceuticals Inc. Piperidin-1-yl-2,2-dialkylpropanonearylsulfonamide derivatives
EP0661266A1 (de) * 1993-12-27 1995-07-05 Toa Eiyo Ltd. Substituierte cyclische Aminverbindungen als 5HT2 Antagonisten
US5728835A (en) * 1993-12-27 1998-03-17 Toa Eiyo, Ltd. Substituted cyclic amine compound, production process thereof and pharmaceutical composition for circulatory organ use containing the same
JPH09249566A (ja) * 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ピペリジン化合物含有ケモカイン受容体拮抗剤
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
CZ425598A3 (cs) * 1996-06-27 1999-08-11 Smithkline Beecham Corporation Antagonista IL-8 receptoru
US6323206B1 (en) * 1996-07-12 2001-11-27 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor
EP1003514A4 (de) * 1997-07-25 2000-10-11 Merck & Co Inc Cyclische amine modulatoren der chemokinrezeptoren
IL125658A0 (en) * 1997-08-18 1999-04-11 Hoffmann La Roche Ccr-3 receptor antagonists
WO1999037619A1 (en) * 1998-01-21 1999-07-29 Millennium Pharmaceuticals, Inc. Chemokine receptor antagonists and methods of use therefor

Also Published As

Publication number Publication date
BR9915403A (pt) 2001-08-14
DE69921351T2 (de) 2006-03-09
PE20001303A1 (es) 2000-11-30
JP2002529531A (ja) 2002-09-10
FR2785902A1 (fr) 2000-05-19
AR029150A1 (es) 2003-06-18
EP1131291B1 (de) 2004-10-20
IT1307062B1 (it) 2001-10-23
ITTO990990A0 (it) 1999-11-16
ZA200103249B (en) 2002-07-22
CN1326441A (zh) 2001-12-12
DE19955340A1 (de) 2000-05-31
US6140344A (en) 2000-10-31
UY25804A1 (es) 2001-07-31
GB9926969D0 (en) 2000-01-12
EP1131291A1 (de) 2001-09-12
JP3475177B2 (ja) 2003-12-08
TR200101155T2 (tr) 2001-09-21
GB2343891A (en) 2000-05-24
DE69921351D1 (de) 2004-11-25
WO2000029377A1 (en) 2000-05-25
AU1045900A (en) 2000-06-05
FR2785902B1 (fr) 2003-09-26
AU757747B2 (en) 2003-03-06
CO5150176A1 (es) 2002-04-29
GB2343891B (en) 2001-05-30
ES2160525B1 (es) 2002-06-16
PT1131291E (pt) 2005-01-31
CA2350722A1 (en) 2000-05-25
CN1163484C (zh) 2004-08-25
ES2160525A1 (es) 2001-11-01
ITTO990990A1 (it) 2001-05-16
KR20010087395A (ko) 2001-09-15
ES2230899T3 (es) 2005-05-01

Similar Documents

Publication Publication Date Title
DE69921351D1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
DE69812096D1 (de) Neuropeptid y rezeptorantagonisten
NO20012411D0 (no) Pyrrolidin-derivater-CCR-3-reseptorantagonister
IS5706A (is) Adenosín A3 viðtakastillar
DE69734833D1 (de) Vitronektin rezeptor antagonisten
NO20001100D0 (no) IL-8 reseptorantagonister
NO993586D0 (no) K-8 reseptor antagonister
DK1009732T3 (da) 1-Amino-alkylcyclohexan NMDA receptor antagonister
CY2010003I2 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
DE69905248T2 (de) Neuropeptid y5-rezeptorantagonisten
EP0986385A4 (de) Antagonisten des gonadorelins
ATE315035T1 (de) Ccr-3-rezeptor-antagonisten
ID24726A (id) Antagonis-antagonis reseptor trombin
ATE272632T1 (de) Muskarin-rezeptor antagonisten
ID26223A (id) Antagonis reseptor vitronektin
ID24162A (id) Antagonis-antagonis reseptor vitronektin
DE69838874D1 (de) Il-8 rezeptor-antagonisten
ID28811A (id) Antagonis reseptor vitronektin
DE69831413T2 (de) Il-8 rezeptor antagonisten
DE69824837D1 (de) Il-8-rezeptor-antagonisten
NO20010620D0 (no) Vitronektinreseptor-antagonister
ID22978A (id) Antagonis reseptor endotelin
NO20010353L (no) IL-8 reseptor-antagonist
EP0957908A4 (de) Antagonisten des fibrinogen rezeptors
TR199601082A3 (tr) Entegrin reseptör antagonistleri.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1131291

Country of ref document: EP

REN Ceased due to non-payment of the annual fee